PAREXEL International is a multinational contract research organization , based in Waltham, Massachusetts and founded in 1982 by Josef H. von Rickenbach and Anne Sayigh. It provides services for companies in the pharmaceutical, biotechnology and medical device industries, including consulting, clinical studies and market launch. The name PAREXEL comes from Paracelsus, a Swiss physician considered as the father of modern toxicology. PAREXEL employs more than 15,000 people worldwide in over 50 countries and has supported leading biotechnology companies and several large pharmaceutical companies to bring new drugs to the market.The company has been ranked to FlexJobs' list of 100 Top Companies for Remote Jobs in 2014.The company provides services during all phases of the development of a drug, from planning to commercialization. It includes strategy development, clinical trials management, data management, biostatistical analysis, regulatory affairs, drug development consulting, medical marketing, training, publishing and advanced eClinical technology solutions. Wikipedia.


Time filter

Source Type

— Market Scenario The major growth driver of Mobile Cloud Market includes increasing usage of mobile apps and services, growing market of smartphones and tablets, and growing digital technology market among others. However, data security and privacy policy in a business are some of the factors which are hindering the growth of Mobile Cloud Market. Key Players • Cisco Systems Inc. (U.S.), • Amazon web services (U.S.), • Oracle Inc. (U.S.), • Microsoft Corporation (U.S.), • Google Inc. (U.S.), • IBM Corporation (U.S.), • Akamai Technologies (U.S.), • Alibaba Group (China), • EMC Corporation (U.S.), • Apple Inc. (U.S.). Industry News: • EMC Corporation has formed an alliance with Parexel International Corporation to provide cloud-based document and regulatory information services. Parexel is a one of the leader in biopharmaceutical services and thus would provide life science content and information management structured within a private cloud environment. • Akamai Technologies has done partnership with KT, one of the leading telecommunication company in Korea to build ucloud biz KT’s cloud service with Akamai technologies to expand its business in Korea region. Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Mobile Cloud Market Research Report- Global Forecast to 2022” Objective Study of Mobile Cloud Market: • To provide detailed analysis of the market structure along with forecast for the next five years of the various segments and sub-segments of the global Mobile Cloud Market. • To provide insights about factors affecting the market growth. • To Analyze the Mobile Cloud Market based on various factors- porters five force analysis, mega trend analysis, macroeconomic indicators etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW). • To provide country level analysis of the market with respect to the current market size and future prospective. • To provide country level analysis of the market for segment by service model, by deployment, by applications and sub-segments The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Related Reports Global Cloud Gaming Market on Market Information, by Type (Video streaming, File Streaming), by Cloud (Public, Private, Hybrid), by Server (G-Cluster, Play Station, Gamenow), by End user (Serious Gamer, Social Gamer, Core Gamer) - Forecast 2016-2022.Know more about this report @ https://www.marketresearchfuture.com/reports/cloud-gaming-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com


News Article | February 2, 2017
Site: www.realwire.com

Acquisition will strengthen and add scale to current commercialisation and medical affairs services LONDON, February 2, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, LLC (“TMAC”), a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries. The acquisition is expected to close in February. Terms of the transaction were not disclosed. Founded in 2007, TMAC is a full-service contract medical organisation. TMAC offers strategic and tactical medical science liaison (MSLs) and clinical nurse educator support services in addition to medical affairs consulting, medical communications support, and direct placement services. TMAC is based in Kennesaw, Georgia, and has approximately 200 U.S.-based employees. Outsourcing medical affairs services presents a compelling option for biopharmaceutical companies as a way to reduce fixed costs. The increasingly complex nature of new products, and the need to demonstrate the therapeutic and reimbursement value of a product, is creating demand for credentialed healthcare professionals, such as MSLs, to lead clinically robust dialogues with key medical stakeholders on a peer-to-peer level. “The commercialisation-outsourcing market continues to grow as biopharmaceutical clients increasingly require medical affairs solutions to optimise awareness and understanding of their products in development or already on the market,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “As a company, we are focused on opportunities within commercialisation, market access, regulatory, pharmacovigilance, and medical outsourcing. With TMAC, PAREXEL will gain new and distinct medical affairs outsourcing capabilities that will strengthen and expand our commercialisation and market access offerings.” “We are excited to become a part of PAREXEL and offer our clients a comprehensive range of services delivered by a single company. Working together, PAREXEL and TMAC will deliver greater value to clients and meet evolving client needs, throughout the lifecycle of their products,” added Evan Demestihas, MD, RPh, Chief Executive Officer, TMAC. After the close of the acquisition, the TMAC management team will remain in place and continue to manage its employees and the services it currently provides to clients. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete the acquisition of The Medical Affairs Company, LLC and additional acquisitions, and to integrate newly acquired businesses including the acquisitions of The Medical Affairs Company, LLC, ExecuPharm, Inc. and Health Advances, LLC, or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


LONDON, February 28, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL's Business Review Committee, the Company's senior-most leadership team, and assist in developing and implementing PAREXEL's strategic objectives. Mr. Harford will be based at the Company’s corporate headquarters in Waltham, Massachusetts. “Simon brings to PAREXEL more than three decades of global financial management and investor relations experience in the pharmaceutical industry. During his career, he has successfully managed large global finance functions, implemented transformational projects, and improved operational effectiveness,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Simon’s leadership will strengthen our ability to accelerate growth and improve profitability as we implement our corporate strategy.” Mr. Harford joins PAREXEL from GlaxoSmithKline plc (GSK), where he most recently served as Senior Vice President, Finance, for the company’s Global Pharmaceuticals business based at GSK’s global headquarters in Brentford, England. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., in New York. Additionally, he spent two decades with Eli Lilly and Company in various finance leadership roles across Europe and in Indianapolis, most notably as Head of Investor Relations and as Vice President and Controller. “PAREXEL has a long and distinguished history of providing innovative services to the biopharmaceutical industry, a record that has positioned the Company for long-term growth,” said Mr. Harford. “I look forward to working with PAREXEL’s management team as we leverage growth opportunities and deliver value to our shareholders.” Mr. Harford, a native of the United Kingdom, holds an MBA from the University of Virginia’s Darden Graduate School of Business. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL's Business Review Committee, the Company's senior-most leadership team, and assist in developing and implementing PAREXEL's strategic objectives. Mr. Harford will be based at the Company’s corporate headquarters in Waltham, Massachusetts. “Simon brings to PAREXEL more than three decades of global financial management and investor relations experience in the pharmaceutical industry. During his career, he has successfully managed large global finance functions, implemented transformational projects, and improved operational effectiveness,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Simon’s leadership will strengthen our ability to accelerate growth and improve profitability as we implement our corporate strategy.” Mr. Harford joins PAREXEL from GlaxoSmithKline plc (GSK), where he most recently served as Senior Vice President, Finance, for the company’s Global Pharmaceuticals business based at GSK’s global headquarters in Brentford, England. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., in New York. Additionally, he spent two decades with Eli Lilly and Company in various finance leadership roles across Europe and in Indianapolis, most notably as Head of Investor Relations and as Vice President and Controller. “PAREXEL has a long and distinguished history of providing innovative services to the biopharmaceutical industry, a record that has positioned the Company for long-term growth,” said Mr. Harford. “I look forward to working with PAREXEL’s management team as we leverage growth opportunities and deliver value to our shareholders.” Mr. Harford, a native of the United Kingdom, holds an MBA from the University of Virginia’s Darden Graduate School of Business. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


News Article | January 26, 2017
Site: www.realwire.com

Simplified, end-to-end solution will help biopharmaceutical clients provide compassionate access to their treatments for patients London, January 26, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an expanded Managed Access Programs service. PAREXEL now offers end-to-end expertise for the design, development, and delivery of managed access programs to help biopharmaceutical companies provide access to investigational medical products for patients in need. Managed Access Programs provide use of an investigational medical product by a patient when enrollment in a clinical trial is not possible. Often called “Compassionate Use” or “Expanded Access,” these programs allow patients to obtain direct and rapid access to a therapy while regulatory or reimbursement processes are still ongoing. A treating physician or patient may request such access in the absence of comparable or satisfactory alternative therapy or when the investigational product presents less risk than the disease or condition for the patient. “Managed Access Programs can be complex to operationalise. They require expertise and experience in managing these types of programs as well as a global network to deliver these solutions with key agencies, regulators, local decision makers, and the medical community,” said Peggy Schrammel, Vice President, Managed Access Programs, PAREXEL. “PAREXEL’s unique configuration of simplified, end-to-end services for Managed Access Programs includes seasoned operational teams, global regulatory expertise, proprietary technology, and global clinical logistics.” In addition to designing all aspects of the program, PAREXEL clinical logistics experts manage the supply of the medicinal product, ensuring on-time delivery and ongoing availability of product for each enrolled patient on a worldwide basis. Leading global safety experts oversee all aspects of pharmacovigilance and reporting requirements of safety events, while market access experts help clients determine the utility of collected data for commercial and medical stakeholders as indications of real world value. PAREXEL’s expanded Managed Access Programs service is available around the world as part of the MyAccessProgramsTM platform, a proprietary technology of PAREXEL. The platform can support multiple Managed Access Programs for a client, including patient identification, physician enrollment, stakeholder communications management, and drug supply management. MyAccessProgramsTM platform also provides clients with real-time progress oversight. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 18,750 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and MyAccessPrograms are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


LONDON, February 13, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone® RTSM (randomisation and trial supply management) service. The app is designed to enhance clinical trial supply management processes, increase patient safety, and improve the chain of custody record for clinical supplies. Using built-in barcode scanning capabilities, clinical trial site staff, including principal investigators (PIs), study nurses, and clinical research associates (CRAs), can utilise the app to streamline common clinical trial responsibilities. Tasks including confirming correct treatment allocation, dispensing to patients, and processing of medicinal product returns can now be managed more efficiently, reducing time and human errors. “Clinical trials management is often hampered by administrative supply-related tasks at site locations. Simplifying systems and processes and removing manual data entry can save staff time and increase patient safety,” said Ken Faulkner, Corporate Vice President, PAREXEL Informatics. “Our mobile app is the latest extension of the ClinPhone RTSM service, further demonstrating our commitment to simplifying the drug development journey through the innovative application of social, mobile, analytic, and cloud technologies.” PAREXEL’s ClinPhone RTSM service has been deployed on over 3,700 studies and more than 2.5 million patients, with the largest of those studies randomising and supplying more than 60,000 patients. The ClinPhone RTSM mobile app is available worldwide for use on Android and iOS platforms. For more details, please visit: https://www.parexel.com/solutions/informatics/randomization-and-trial-supply-management/rtsm-mobile-app. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


BOSTON, October 6, 2016 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites. An increasing number of medicinal products require a temperature-controlled supply chain to maintain product integrity during transport, including approximately 75 percent of biological drugs, 10 to 15 percent of small molecule therapies, 100 percent of vaccines, and a large percent of biologic samples and diagnostic tools[1]. Temperature deviations and shipment delays can impact patient safety, create patient retention issues, and cause additional manufacturing and shipment costs. Supported by PAREXEL’s Clinical Trial Supply & Logistics global depot and service network, PAREXEL’s Active Tracking service utilizes supply chain monitoring technology to detect incidents, such as shipment delays, shipment diversions, and temperature deviations. When combined with PAREXEL ClinPhone® RTSM interactive response technology (IRT), temperature and location data is automatically sent in near real-time to clinical trial sites for assessment. This integration enables greater automated preventive or remedial actions, such as release, quarantine, and automatic re-order of temperature-controlled products, simplifying temperature management for sites and sponsors. “In the past, an investigational site had to wait until it received a shipment and downloaded the data from the temperature logger to find out if a drug’s temperature had been compromised,” said Sanjay Vyas, Corporate Vice President, Clinical Trial Supplies & Logistics, PAREXEL. “With PAREXEL’s Active Tracking service, we can monitor IMPs from packaging at our depots through transit to clinical trial sites, in near real-time. This innovation in clinical supply chain management allows us to quickly respond to any temperature complications, which can reduce safety risks for patients as well as manufacturing and shipment costs for clients.” About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and had approximately 18,600 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


LONDON, December 18, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that its Country Allocation Technology won the Best Technological Development in Clinical Trials Award at the 2015 Scrip Awards. The award recognises the importance of PAREXEL’s Country Allocation Technology across the drug development value chain. Country selection, patient recruitment, and patient enrollment are among the most fundamental needs in drug development. Delays in one of these areas can cost a biopharmaceutical company time and money in getting a new drug to a patient in need. To address this challenge, PAREXEL developed its Country Allocation Technology, providing feasibility teams a data-driven tool for country selection. “This award honors PAREXEL’s long history of innovation in clinical trial technology,” said Paul Evans, Vice President, Site Strategy & Start-Up, PAREXEL. “Our Country Allocation Technology provides a data-driven approach to country selection for a clinical trial. By looking at a variety of data, we provide clients with a clear ranking of countries for their specific trial based on medical, clinical, operational, regulatory, and financial criteria.” PAREXEL was one of six finalists in the Best Technological Development in Clinical Trials category, which focused on identifying the product that represents the best advance in supporting clinical trial management. In selecting PAREXEL as the winner, the judges explained: “The cost savings are massive. If we can get the feasibility right, we can progress studies more efficiently.” “At PAREXEL, we believe the world would be a healthier place if the journey between science and new treatments were simpler. We innovate continuously to provide technology services that empower our clients to make data-driven business decisions, helping to reduce risk and to speed time to market,” added David Kiger, Vice President, Product Strategy, PAREXEL Informatics. About the Scrip Awards Best Technological Development in Clinical Trials Award The Best Technological Development in Clinical Trials Award recognizes the vital importance of using the most sophisticated platforms to catalyze and optimize data gathering during clinical trials. It celebrates the advances in software and applications that are playing a pivotal role in the trial process, from patient recruitment and compliance, to managing and mining outcomes or safety data. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,620 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com. PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners. This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.


Patent
Parexel International | Date: 2014-02-07

Methods and apparatus for facilitating monitoring in a clinical trial. The method includes acts of receiving data from at least one information technology system configured to process clinical trial data, and assigning a site prioritization to each of a plurality of sites for at least one clinical trial associated with the at least one information technology system. Assigning a site prioritization is based, at least in part, on the received data. The method further includes an act of outputting an indication of the site prioritization.


Patent
Parexel International | Date: 2010-11-02

A computer-based system configured to present a user interface that enables a user to access multiple clinical trial systems via a common secure web-based interface. Data integration and reconciliation achieved using an integration platform, in which multiple clinical trial systems are connected to a central messaging hub, provides an integrated clinical trial workflow system that reduces the redundancy in data entry and functionality present in conventional clinical trial workflow systems that employ standalone systems for various aspects of clinical trial management. Aggregation of data using the integration platform provides clinical trial directors with consolidated useful information for making management decisions and the user interface may be dynamically configured based, at least in part, on user access credentials resulting in a more efficient workflow for administrators of a clinical trial.

Loading Parexel International collaborators
Loading Parexel International collaborators